Want to see AU:PTX full AI Analyst Report?
Total Valuation
Prescient Therapeutics Limited has a market cap or net worth of AU$71.50M. The enterprise value is AU$55.34.
Market CapAU$71.50M
Enterprise ValueAU$55.34
Share Statistics
Prescient Therapeutics Limited has 1,051,514,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,051,514,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Prescient Therapeutics Limited’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -49.23%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.43
Return on Invested Capital (ROIC)-49.23%
Return on Capital Employed (ROCE)-0.74
Revenue Per Employee0.00
Profits Per Employee-2.33M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Prescient Therapeutics Limited is ―. Prescient Therapeutics Limited’s PEG ratio is 0.35.
PE Ratio―
PS Ratio0.00
PB Ratio4.41
Price to Fair Value4.41
Price to FCF-8.67
Price to Operating Cash Flow-9.61
PEG Ratio0.35
Income Statement
In the last 12 months, Prescient Therapeutics Limited had revenue of 0.00 and earned -7.00M in profits. Earnings per share was >-0.01.
Revenue0.00
Gross Profit-110.34K
Operating Income-10.59M
Pretax Income-10.44M
Net Income-7.00M
EBITDA-10.48M
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -7.22M and capital expenditures -2.00, giving a free cash flow of -7.22M billion.
Operating Cash Flow-7.22M
Free Cash Flow-7.22M
Free Cash Flow per Share>-0.01
Dividends & Yields
Prescient Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.37
52-Week Price Change59.52%
50-Day Moving Average0.08
200-Day Moving Average0.07
Relative Strength Index (RSI)49.13
Average Volume (3m)1.08M
Important Dates
Prescient Therapeutics Limited upcoming earnings date is Feb 19, 2027, TBA (Not Confirmed).
Last Earnings DateAug 20, 2026
Next Earnings DateFeb 19, 2027
Ex-Dividend Date―
Financial Position
Prescient Therapeutics Limited as a current ratio of 7.14, with Debt / Equity ratio of 1.57%
Current Ratio7.14
Quick Ratio7.14
Debt to Market Cap<0.01
Net Debt to EBITDA0.84
Interest Coverage Ratio-989.90
Taxes
In the past 12 months, Prescient Therapeutics Limited has paid -3.44M in taxes.
Income Tax-3.44M
Effective Tax Rate0.33
Enterprise Valuation
Prescient Therapeutics Limited EV to EBITDA ratio is -5.13, with an EV/FCF ratio of -7.45.
EV to Sales0.00
EV to EBITDA-5.13
EV to Free Cash Flow-7.45
EV to Operating Cash Flow-7.45
Balance Sheet
Prescient Therapeutics Limited has AU$9.03M in cash and marketable securities with AU$222.97K in debt, giving a net cash position of AU$8.81M billion.
Cash & Marketable SecuritiesAU$9.03M
Total DebtAU$222.97K
Net CashAU$8.81M
Net Cash Per Share<AU$0.01
Tangible Book Value Per ShareAU$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Prescient Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast25.27%